- Home
- KGEI vs TLSI Comparison
KGEI vs TLSI Comparison
Compare KGEI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- TLSI
- Stock Information
- Founded
- KGEI 2008
- TLSI 2010
- Country
- KGEI United States
- TLSI United States
- Employees
- KGEI N/A
- TLSI N/A
- Industry
- KGEI
- TLSI Medical Specialities
- Sector
- KGEI
- TLSI Health Care
- Exchange
- KGEI Nasdaq
- TLSI Nasdaq
- Market Cap
- KGEI 131.8M
- TLSI 150.3M
- IPO Year
- KGEI N/A
- TLSI N/A
- Fundamental
- Price
- KGEI $6.62
- TLSI $4.93
- Analyst Decision
- KGEI
- TLSI Strong Buy
- Analyst Count
- KGEI 0
- TLSI 6
- Target Price
- KGEI N/A
- TLSI $11.75
- AVG Volume (30 Days)
- KGEI 55.8K
- TLSI 33.1K
- Earning Date
- KGEI 11-12-2024
- TLSI 11-14-2024
- Dividend Yield
- KGEI N/A
- TLSI N/A
- EPS Growth
- KGEI 2.07
- TLSI N/A
- EPS
- KGEI 0.48
- TLSI N/A
- Revenue
- KGEI $54,654,000.00
- TLSI $26,891,000.00
- Revenue This Year
- KGEI $15.83
- TLSI $60.96
- Revenue Next Year
- KGEI $23.96
- TLSI $53.65
- P/E Ratio
- KGEI $13.80
- TLSI N/A
- Revenue Growth
- KGEI 16.56
- TLSI 67.90
- 52 Week Low
- KGEI $2.84
- TLSI $3.50
- 52 Week High
- KGEI $7.00
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- KGEI 72.33
- TLSI 56.22
- Support Level
- KGEI $6.00
- TLSI $4.53
- Resistance Level
- KGEI $6.28
- TLSI $4.92
- Average True Range (ATR)
- KGEI 0.39
- TLSI 0.29
- MACD
- KGEI 0.05
- TLSI -0.02
- Stochastic Oscillator
- KGEI 80.21
- TLSI 50.63
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. Its segments include the United States, Canada and Others. The company derives a majority of its revenue from the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.